Anew Medical
Biotechnology company developing cell and gene therapy candidates based on a licensed α‑Klotho gene construct (s‑KL) for neurodegenerative and age-related disorders. The organization focuses on R&D of gene and cell therapy delivery modalities, preclinical evaluation in animal models, and building internal capabilities across product development through commercialization. Lead development targets include ALS, Alzheimer’s disease, and Parkinson’s disease.
Industries
Nr. of Employees
small (1-50)
Products
Gene therapy candidates expressing secreted/truncated Klotho (s‑KL)
A portfolio of investigational gene therapy constructs designed to increase Klotho protein levels via multiple delivery modalities (viral vectors, lipid‑complexed DNA, autologous cell transfection) for treatment of neurodegenerative and age‑related disorders.
Gene therapy candidates expressing secreted/truncated Klotho (s‑KL)
A portfolio of investigational gene therapy constructs designed to increase Klotho protein levels via multiple delivery modalities (viral vectors, lipid‑complexed DNA, autologous cell transfection) for treatment of neurodegenerative and age‑related disorders.
Services
Collaborative research and licensing agreements with academic institutions to develop gene therapy candidates.
Preclinical program execution for gene and cell therapy candidates, including efficacy studies in animal models of neurodegenerative disease.
Strategic evaluation of licensing, acquisition, partnership, and commercialization pathways for investigational therapeutics.
Collaborative research and licensing agreements with academic institutions to develop gene therapy candidates.
Preclinical program execution for gene and cell therapy candidates, including efficacy studies in animal models of neurodegenerative disease.
Strategic evaluation of licensing, acquisition, partnership, and commercialization pathways for investigational therapeutics.
Expertise Areas
- Cell and gene therapy
- Neurodegenerative disease therapeutics (ALS, Alzheimer’s, Parkinson’s)
- Viral vector design and delivery optimization
- Non‑viral DNA delivery formulations
Key Technologies
- Gene therapy
- Viral vector platforms
- Lipid‑complexed DNA delivery
- Recombinant protein expression
News & Updates
Default WordPress blog post on site (placeholder).
Licensed an α‑Klotho gene therapy platform on an exclusive worldwide basis from an academic institution to develop gene and cell therapy products.
Default WordPress blog post on site (placeholder).
Licensed an α‑Klotho gene therapy platform on an exclusive worldwide basis from an academic institution to develop gene and cell therapy products.